Kaposi's sarcoma primary prevention

Jump to navigation Jump to search

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma primary prevention

CDC on Kaposi's sarcoma primary prevention

Kaposi's sarcoma primary prevention in the news

Blogs on Kaposi's sarcoma primary prevention

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [3]

Overview

There are no established measures for the primary prevention of Kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease such as avoiding high risk behavior and using antiviral drugs.

Primary Prevention

There are no established measures for the primary prevention of Kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease as followings:[1][2]

References

  1. Casper C, Wald A (2007). "The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma". Curr. Top. Microbiol. Immunol. 312: 289–307. PMID 17089802.
  2. Goedert, J. J. (2002). "Risk Factors for Classical Kaposi's Sarcoma". CancerSpectrum Knowledge Environment. 94 (22): 1712–1718. doi:10.1093/jnci/94.22.1712. ISSN 1460-2105.

Template:WH Template:WS


References


Template:WH Template:WS